Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.04M | 10.84M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.04M | 10.84M | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 1.04M | 10.84M | -- | -- |
| SG&A Expenses | 8.74M | 7.87M | 7.31M | 5.54M | 8.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.13M | 25.77M | 102.34M | 25.89M | 21.03M |
| Operating Income | -28.13M | -24.73M | -91.49M | -25.89M | -21.03M |
| Income Before Tax | -24.84M | -23.28M | -90.40M | -24.61M | -21.79M |
| Income Tax Expenses | -- | -- | 2.00M | -- | -- |
| Earnings from Continuing Operations | -24.84M | -23.28M | -92.40M | -24.61M | -21.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.84M | -23.28M | -92.40M | -24.61M | -21.79M |
| EBIT | -28.13M | -24.73M | -91.49M | -25.89M | -21.03M |
| EBITDA | -28.07M | -24.67M | -91.44M | -25.86M | -21.03M |
| EPS Basic | -0.74 | -0.70 | -4.01 | -1.27 | -4.93 |
| Normalized Basic EPS | -0.50 | -0.44 | -2.45 | -0.79 | -3.08 |
| EPS Diluted | -0.74 | -0.70 | -4.01 | -1.27 | -4.93 |
| Normalized Diluted EPS | -0.50 | -0.44 | -2.45 | -0.79 | -3.08 |
| Average Basic Shares Outstanding | 33.42M | 33.29M | 23.06M | 19.43M | 4.42M |
| Average Diluted Shares Outstanding | 33.42M | 33.29M | 23.06M | 19.43M | 4.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |